More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The National Highway Traffic Safety Administration’s Office of Emergency Medical Services today released an updated agenda for the nation’s EMS sys
Headline
The Department of Health and Human Services has released medical management guidelines and other resources to help the emergency response community prepare for…
Insights and Analysis
Hospitals and health systems are using command center technology in addition to their electronic medical records to help them stay organized during a disaster…
Headline
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
Headline
The House of Representatives last night passed legislation (H.R. 269) that includes the Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary of Preparedness and Response will host a Jan. 29 webinar on its new toolkit.